HIF1A and renal cell carcinoma: Interestingly, another mTORC1/2 dual inhibitor AZD-2014 was also able to downregulate HIF-1α/2α and cyclin D expression and further inhibit RCC cell proliferation preclinically (Zheng et al., 2015).